If you are wondering whether NEC at ¥4,200 is offering good value today, it helps to first line up the recent share performance with how the stock is currently priced.
The stock has returned 4.1% over the last week and 0.3% over the last month, while year to date it is down 22.7% and the 1 year return sits at 12.6%, with a very large gain over 3 years and a 333.9% return over 5 years.
These moves sit against a backdrop of ongoing coverage of NEC's role in software and IT solutions, along...
Wondering whether Sumitomo Metal Mining is still reasonably priced after a strong run, or if the stock has moved ahead of its underlying value?
The share price last closed at ¥10,615, alongside returns of 11.4% over 7 days, 2.5% over 30 days, 59.9% year to date, 246.0% over 1 year, 164.7% over 3 years and 159.8% over 5 years.
Recent coverage has focused on how these share price moves relate to the broader metals and mining theme and shifting sentiment toward resource companies. Headlines...
Investors may be wondering whether KDDI is fairly priced or offering hidden value right now, especially after its recent share price moves.
The stock last closed at ¥2,528.5, with returns of a 0.8% decline over 7 days, 6.7% decline over 30 days, 7.5% decline year to date, 2.0% decline over 1 year, 25.6% over 3 years, and 67.4% over 5 years. Taken together, this provides a mixed picture of recent pressure and longer term strength.
Recent attention on KDDI has focused on how its share price...
If you are wondering whether ASICS stock still offers value after its strong run, or if you might be late to the story, this article breaks down what the current price could be implying.
The stock last closed at ¥4,640, with returns of 6.9% over 7 days, 4.7% over 30 days, 20.6% year to date and 40.7% over 1 year, while the 3 year return is very large and the 5 year return is close to 8x.
Recent coverage has focused on ASICS as a long term compounder in the athletic footwear space. Attention...
Niterra Co., Ltd. has released its full-year results for the period ended March 31, 2026, reporting sales of ¥731,207 million, net income of ¥112,892 million, and basic earnings per share from continuing operations of ¥570.43.
These figures give investors an updated view of Niterra’s overall scale and profitability as the company closes its latest fiscal year.
We will now look at how Niterra’s full-year profitability profile shapes the company’s investment narrative and future...
Rakuten Group (TSE:4755) is backing Swarmer, Inc.'s autonomy solutions in Japan’s advanced unmanned systems sector.
The company is linking this support with its ongoing humanitarian engagement and technology ties in Ukraine.
The move connects Rakuten’s digital capabilities with robotics and autonomy projects in Japan’s manufacturing and infrastructure fields.
For you as an investor, this places Rakuten Group’s core digital and platform business alongside a more hardware-focused field:...
Fujitsu (TSE:6702) has drawn fresh attention after its board approved a share repurchase program of up to 100,000,000 shares for ¥150,000 million, alongside full year results that highlight higher net income and earnings per share.
See our latest analysis for Fujitsu.
The share repurchase and stronger earnings backdrop helped lift Fujitsu’s share price. It is up 5.37% on a 1-day share price return but still shows a 24.81% decline year to date, while the 5-year total shareholder return is...
If you are wondering whether Daiichi Sankyo Company at around ¥2,600 per share offers good value today, it helps to step back and consider what the current price may already be pricing in.
The stock has seen a 0.4% return over the last 7 days, a 9.5% decline over 30 days, and is down 26.3% year to date and 26.1% over the past year, which can change how investors think about both upside potential and risk.
These moves come against a backdrop where investors are reassessing pharmaceutical...
Shin-Etsu Chemical (TSE:4063) has implemented a new share buyback program alongside its latest full year results, providing investors with updated information on both capital returns and recent business performance.
See our latest analysis for Shin-Etsu Chemical.
The buyback and earnings announcement appear to have coincided with a sharp shift in sentiment, with the stock posting a 1 day share price return of 8.54% and a 30 day return of 17.30%. This has contributed to a 1 year total...
Unicharm Corporation recently held its Q1 2026 earnings call on May 8, following its scheduled earnings announcement for early May.
Investor attention has centered on Unicharm’s strong balance sheet, with very low debt-to-equity and solid liquidity underpinning confidence ahead of results.
With Unicharm’s robust balance sheet in focus, we’ll now examine how this earnings update shapes the company’s broader investment narrative.
Find 15 companies with promising cash flow potential yet trading...
For readers wondering whether Renesas Electronics at ¥3,623 is still attractively priced or already running ahead of itself, this article breaks down what the current share price might be implying about value.
The stock has posted returns of 12.8% over the last week, 56.7% over the last month, 62.8% year to date, and 114.3% over the past year, which may signal that expectations or perceived risks have shifted meaningfully.
Recent coverage has focused on Renesas Electronics in the context of...
Earlier today, Asian stock markets rallied as global crude prices eased on reports of potential peace talks in the Persian Gulf, lifting indices across Hong Kong, Shanghai, and Tokyo.
Within this broader upswing, Ibiden, a Japanese semiconductor components maker, stood out as a key beneficiary of the renewed optimism in Japanese equities.
Next, we’ll examine how Ibiden’s strong participation in this oil-driven Asian market rebound shapes its broader investment narrative for...
In April 2026, Komatsu Ltd. announced it would repurchase up to 25,000,000 shares for ¥100,000 million, cancel the repurchased stock, reported full-year 2026 earnings of ¥4,132,751 million in sales and ¥376,391 million in net income, and issued guidance and dividend plans for fiscal 2027.
This combination of a sizeable cancellation-backed buyback and detailed earnings and dividend outlook provides fresh insight into how Komatsu is balancing capital returns with reinvestment needs.
We will...
Earlier this month, Takeda Pharmaceutical reported that its pivotal Phase 2/3 trial of investigational PID therapy TAK-881 met its primary pharmacokinetic endpoint, showing comparable IgG exposure, efficacy and safety to HYQVIA, while potentially allowing patients to receive equivalent immunoglobulin doses in roughly half the infusion volume.
Because TAK-881 may offer shorter, lower-volume infusions with once-monthly flexibility, it could meaningfully change treatment convenience for Primary...
Earnings and dividend review put Shin-Etsu PolymerLtd (TSE:7970) in focus
Shin-Etsu PolymerLtd (TSE:7970) has just reported full year results to March 31, 2026 and held a board meeting to consider revising its dividend forecast, putting earnings quality and shareholder returns under closer investor scrutiny.
See our latest analysis for Shin-Etsu PolymerLtd.
The recent earnings announcement and board meeting on the dividend forecast came against a strong backdrop, with Shin-Etsu PolymerLtd’s...
What Shiseido’s New Bond Shelf Could Mean for the Stock
Shiseido Company (TSE:4911) has filed a shelf registration to issue up to ¥300 billion in bonds, a move that gives the company flexibility to raise debt funding when conditions appear favorable.
For you as a shareholder or potential investor, this filing matters because it may influence Shiseido’s future capital structure, interest costs, and capacity to fund projects, acquisitions, or balance sheet adjustments, without immediately...
Oncology pipeline expectations draw fresh focus to Daiichi Sankyo
Positive sentiment around Daiichi Sankyo Company (TSE:4568) is being driven by expectations that its oncology portfolio, including upcoming pivotal data and regulatory submissions across several cancer types, could reshape how investors view the stock.
See our latest analysis for Daiichi Sankyo Company.
Despite the excitement around its oncology portfolio, Daiichi Sankyo’s share price return has been weak, with an 8.45% 1 month...
Sumitomo Corporation recently reported full-year results to March 31, 2026, with revenue of ¥7,337,259 million and net income of ¥600,334 million, while also approving a share repurchase program of up to 22,000,000 shares, or 1.84% of outstanding stock, worth ¥80,000 million through March 31, 2027.
Alongside higher earnings, Sumitomo outlined a Medium-Term Management Plan 2026, raised its dividend, and announced a four-for-one share split, underscoring an emphasis on capital efficiency and...